文献速递常见症状与未分化疾病预防保健、筛查与疫苗慢病管理

轻症新冠感染后一年长期新冠结局:全国性队列研究

Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study.
PubMed 文献 · BMJ · 2023-01-11

该回顾性全国队列研究纳入以色列1 913 234名接受SARS-CoV-2 PCR检测者,比较未接种感染者与未感染者的70种长期新冠结局。轻症感染者早期和晚期均见嗅觉味觉障碍、认知障碍、呼吸困难、乏力及心悸风险升高,但多数结局在一年内消退;突破性感染者呼吸困难风险较低。

要点

  • 轻症新冠感染与嗅觉味觉障碍、认知障碍、呼吸困难、乏力、心悸的早期和晚期风险升高相关。
  • 脱发、胸痛、咳嗽、肌痛和呼吸系统疾病仅在感染早期显著增加。
  • 接种疫苗后突破性感染者的呼吸困难风险低于未接种感染者,其他结局风险相似。

核心结论

  • 轻症新冠感染者在感染后一年内存在少量健康结局的风险升高,但大多数结局在诊断后一年内消退。

研究设计与样本

  • 回顾性全国队列研究,基于以色列Maccabi Healthcare Services电子病历,纳入2020年3月1日至2021年10月1日期间接受SARS-CoV-2 PCR检测的1 913 234名全年龄段成员。

主要发现

  • 未接种感染者与未感染者匹配并调整年龄和性别后,早期(30-180天)和晚期(180-360天)嗅觉味觉障碍风险比分别为4.59(95%CI 3.63-5.80)和2.96(95%CI 2.29-3.82),风险差分别为每10 000人19.6(95%CI 16.9-22.4)和11.0(95%CI 8.5-13.6)。
  • 认知障碍早期风险比1.85(95%CI 1.58-2.17)、风险差每10 000人12.8(95%CI 9.6-16.1),晚期风险比1.69(95%CI 1.45-1.96)、风险差13.3(95%CI 9.4-17.3)。
  • 呼吸困难早期风险比1.79(95%CI 1.68-1.90)、风险差每10 000人85.7(95%CI 76.9-94.5),晚期风险比1.30(95%CI 1.22-1.38)、风险差35.4(95%CI 26.3-44.6)。
  • 乏力早期风险比1.78(95%CI 1.69-1.88)、风险差每10 000人108.5(95%CI 98.4-118.6),晚期风险比1.30(95%CI 1.22-1.37)、风险差50.2(95%CI 39.4-61.1)。
  • 心悸早期风险比1.49(95%CI 1.35-1.64)、风险差每10 000人22.1(95%CI 16.8-27.4),晚期风险比1.16(95%CI 1.05-1.27)、风险差8.3(95%CI 2.4-14.1)。

临床怎么用

  • 对轻症新冠感染后持续乏力、呼吸困难、认知障碍、心悸或嗅觉味觉障碍的患者,在全科随访中应评估长期新冠可能性。
  • 多数长期新冠结局在一年内消退,可向患者解释预后并避免过度检查。
  • 接种疫苗后突破性感染者呼吸困难风险较低,支持疫苗接种的益处在长期结局方面。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status. DESIGN: Retrospective nationwide cohort study. SETTING: Electronic medical records from an Israeli nationwide healthcare organisation. POPULATION: 1 913 234 Maccabi Healthcare Services members of all ages who did a polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 1 October 2021. MAIN OUTCOME MEASURES: Risk of an evidence based list of 70 reported long covid outcomes in unvaccinated patients infected with SARS-CoV-2 matched to uninfected people, adjusted for age and sex and stratified by SARS-CoV-2 variants, and risk in patients with a breakthrough SARS-CoV-2 infection compared with unvaccinated infected controls. Risks were compared using hazard ratios and risk differences per 10 000 patients measured during the early (30-180 days) and late (180-360 days) time periods after infection. RESULTS: Covid-19 infection was significantly associated with increased risks in early and late periods for anosmia and dysgeusia (hazard ratio 4.59 (95% confidence interval 3.63 to 5.80), risk difference 19.6 (95% confidence interval 16.9 to 22.4) in early period; 2.96 (2.29 to 3.82), 11.0 (8.5 to 13.6) in late period), cognitive impairment (1.85 (1.58 to 2.17), 12.8, (9.6 to 16.1); 1.69 (1.45 to 1.96), 13.3 (9.4 to 17.3)), dyspnoea (1.79 (1.68 to 1.90), 85.7 (76.9 to 94.5); 1.30 (1.22 to 1.38), 35.4 (26.3 to 44.6)), weakness (1.78 (1.69 to 1.88), 108.5, 98.4 to 118.6; 1.30 (1.22 to 1.37), 50.2 (39.4 to 61.1)), and palpitations (1.49 (1.35 to 1.64), 22.1 (16.8 to 27.4); 1.16 (1.05 to 1.27), 8.3 (2.4 to 14.1)) and with significant but lower excess risk for streptococcal tonsillitis and dizziness. Hair loss, chest pain, cough, myalgia, and respiratory disorders were significantly increased only during the early phase. Male and female patients showed minor differences, and children had fewer outcomes than adults during the early phase of covid-19, which mostly resolved in the late period. Findings remained consistent across SARS-CoV-2 variants. Vaccinated patients with a breakthrough SARS-CoV-2 infection had a lower risk for dyspnoea and similar risk for other outcomes compared with unvaccinated infected patients. CONCLUSIONS: This nationwide study suggests that patients with mild covid-19 are at risk for a small number of health outcomes, most of which are resolved within a year from diagnosis.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Mizrahi B, Sudry T, Flaks-Manov N, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023. PMID: 36631153. doi:10.1136/bmj-2022-072529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。